Medical/Pharmaceuticals
MIM Software Inc. Announces Global Partnership with GenesisCare
CLEVELAND, Feb. 28, 2022 /PRNewswire/ -- MIM Software Inc. announced today a partnership with leading global provider of integrated cancer care, GenesisCare, to increase patient access to world-class care on a global scale. GenesisCare's clinical teams treat more than 400,000 patients at more tha...
2022-02-28 23:15
2212
Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars bus...
2022-02-28 22:15
4683
Inspira Technologies Applauded by Frost & Sullivan for Minimizing the Need for Invasive Mechanical Ventilation with Its Innovative Technology, the ART™ System
Inspira Technologies aims to set a new standard of care in the respiratory care industry by introducing its ART system. SAN ANTONIO, Feb. 28, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the European artificial respiratory market and, based on its findings, recognizesInspira Technolog...
2022-02-28 22:00
2066
PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
SYDNEY, Feb. 28, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in combination with metformin and a ketogenic diet for the treatmen...
2022-02-28 21:00
3403
Argon Medical Devices Celebrates Its 50th Anniversary
Industry leader highlights its longevity and thanks employees for their loyalty and effort FRISCO, Texas, Feb. 28, 2022 /PRNewswire/ -- Argon Medical Devices, Inc., a leading manufacturer of medical devices for interventional procedures, announces its 50th anniversary. This impressive milestone ...
2022-02-28 18:00
3872
Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer
SUZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosing...
2022-02-28 10:03
3620
First-ever Shingles Awareness Week highlights misconceptions about the risk of developing shingles among older adults, and the need for more education
* GSK has launched the inaugural Shingles Awareness Week to educate the general public about shingles in collaboration with the International Federation on Ageing * Over 90% of adults, above the age of 50, already carry the virus that causes shingles, and 1 in 3 adults will develop shingles i...
2022-02-28 10:00
2129
ALPS PHARMA LAUNCHES A NEW QUERCETIN DELIVERY COMPOSITION
HIDA, Japan, Feb. 28, 2022 /PRNewswire/ -- ALPS Pharmaceutical Ind. Co., Ltd. (President:Osamu Ushimaru), a global pharmaceutical company pioneering phytochemicals in medicine and food,today announced the launch of a water-soluble Quercetin delivery composition, Eubioflavonoid® derived from Sopho...
2022-02-28 09:19
2042
ALPS PHARMA LAUNCHES A NEW WATER-SOLUBLE ISOQUERCETIN COMPOSITION WITH HIGHER ABSORPTION RATE
HIDA, Japan, Feb. 28, 2022 /PRNewswire/ -- ALPS Pharmaceutical Ind. Co., Ltd. (President:Osamu Ushimaru), a global pharmaceutical company that pioneered the use of phytochemicals in medicine and food, announced the launch of a new Isoquercetin composition, Eubio®Isoquercetin,today. Eubio®Isoqu...
2022-02-28 09:16
2144
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis
HANGZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it had dosed the first patient with LNK01001 in its Phase II clinical trial on subjects with atopic dermatitis (A...
2022-02-28 08:00
4298
JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the sup...
2022-02-27 18:30
6990
First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial
SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort ...
2022-02-25 22:04
3889
Jean-Luc Herbeaux to become Hovione CEO
LISBON, Portugal, Feb. 25, 2022 /PRNewswire/ -- Hovione today announced that
the Board of Directors and the shareholders have approved the appointment of
Dr. Jean-Luc Herbeaux as Hovione's Chief Executive Officer, effective1st April
2022.
2022-02-25 22:00
3735
Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy
SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the topline results of the phase 3 clinical trial for a triple combination therapy of Enavogliflozin, a new antidiabetic drug with the mechanism of SGLT-2 inhibitor, with Metformin and Gemigliptin. Enav...
2022-02-25 22:00
4042
Terumo and Corazon Sign Collaboration and Co-Marketing Agreement
SOMERSET, N.J., Feb. 25, 2022 /PRNewswire/ -- Terumo Health Outcomes, a division of Terumo Medical Corporation, a leading global medical device manufacturer, has signed a collaboration and co-marketing agreement with Corazon, Inc., a leader in providing consulting, recruitment, interim managemen...
2022-02-25 22:00
4400
PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial
DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (me...
2022-02-25 21:00
3236
Fosun Foundation's First Batch of 250,000 Sets of COVID-19 Rapid Antigen Test Kits Arrives in Hong Kong
HONG KONG, Feb. 25, 2022 /PRNewswire/ -- In an effort to support Hong Kong's fight against the severe fifth wave of COVID-19 epidemic, Fosun Foundation announced last week the donation ofHK$10 million anti-epidemic materials, including COVID-19 rapid antigen test kits and face masks toHong Kong. ...
2022-02-25 12:33
5729
HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets
CHENGDU, China, Feb. 24, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed a three-year drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation ("MTPC"), a Japanese pharma...
2022-02-25 10:00
2291
Insilico Announces Successful Completion of Phase 0 Microdose Trial and Initiates Phase I Clinical Trial for its First AI-discovered Anti-fibrotic Product Candidate with Novel Target
NEW YORK and HONG KONG, Feb. 25, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in a Phase I clinical trial evaluating ISM001-055, the first anti-fibroti...
2022-02-25 00:00
5739
SeekIn Receives CE Mark Approval for SeekInCare® Pan Cancer Early Detection Test
SHENZHEN, China, Feb. 24, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for SeekInCare® Cancer Detection Kit and is now ready to launch this test in European markets. Nearly 10 mill...
2022-02-24 21:34
2305
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9147
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8215
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
8152